NEURELIS JOINS THE EPILEPSY COMMUNITY AT ANNUAL SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
SAN DIEGO, Nov. 16, 2026
Press Release Disclaimer: This is a press release distributed through the XPR Media network. It has not been independently verified by our newsroom.

![]()
NEURELIS JOINS THE EPILEPSY COMMUNITY AT ANNUAL SOFIE’S JOURNEY EPILEPSY AWARENESS DAY AND EDUCATION EXPO AT DISNEYLAND® RESORT
PR Newswire
SAN DIEGO, Nov. 16, 2026
Company’s Ambassadors to share their experiences and connect with epilepsy community
SAN DIEGO, Nov. 16, 2026 /PRNewswire/ — Neurelis, Inc., neuroscience company and innovator behind VALTOCO® (diazepam nasal spray), announced today it will participate in the 14th Annual Sofie’s Journey Epilepsy Awareness Day & Education Expo at Disneyland (EADDL). The Company will also be joined by its Ambassadors who will share their journeys with epilepsy. EADDL, one of the largest gatherings of people with epilepsy, care partners, and healthcare practitioners, was created to help address the unmet needs for increased education for people with epilepsy and their families.
“Participating in the EADDL event and connecting with the epilepsy community is incredibly meaningful to me,” commented DeJah, Neurelis Ambassador, outgoing traveler, and full-time employee who advocates for people living with epilepsy. “It is an honor to speak on behalf of Neurelis and share my experience with VALTOCO, since having VALTOCO has given me the confidence to be a voice for others and venture out knowing I am prepared for an episode of frequent seizures.”
“Being able to treat a seizure when it happens by having access to VALTOCO has given me a sense of security and peace of mind,” commented Ami, Neurelis Ambassador, mom, registered nurse, and care partner of son with Lennox-Gastaut syndrome (LGS), a severe form of epilepsy. “I am grateful our journey with epilepsy has given us the opportunity to collaborate with Neurelis and share our story with those impacted by the challenges of the disease.”
Neurelis will sponsor two presentations on its FDA-approved product VALTOCO® (diazepam nasal spray) at the Expo, highlighting both the medication as an immediate-use treatment for episodes of frequent seizures in patients two years of age and older as well as the experience of its Ambassadors with the product. Each presentation will be followed by a Q&A session.
- Monday, November 16th, 11-11:45 AM PT, Room D Specialty Care and New Therapies: Raman Sankar, MD, PhD, Distinguished Professor of Neurology and Pediatrics at the David Geffen School of Medicine UCLA, and Neurelis Ambassador DeJah
- Tuesday, November 17th, 1:45-2:25pm, Room D Specialty Care and New Therapies: Steve Chung, MD, Professor of Neurology at the University of Arizona College of Medicine – Phoenix and the Director of the Epilepsy Program at the Banner University Medical Center, and Neurelis Ambassador Ami
The Company will also participate in the free education expo on November 16-17th from 9:00 AM to 5:00 PM PT at the Disneyland Hotel in Anaheim, CA, followed by a family dance party on November 17th. Families will spend the day enjoying Disneyland by celebrating Epilepsy Awareness Day on November 18th at Magic Kingdom.
“We at Neurelis deeply value engaging people with epilepsy, their families and care partners, as well as clinicians and other healthcare practitioners at the annual EADDL event. This community gathering is critically important for the exchange of medical information and patient stories as we all advance a shared mission to empower people with epilepsy,” added Neurelis Founder and CEO Craig Chambliss.
About Neurelis
Neurelis, Inc., is a neuroscience company focused on the development and commercialization of therapeutics for the treatment of epilepsy and neurologic disorders characterized by high unmet medical need. The FDA has approved Neurelis’ VALTOCO® (diazepam nasal spray) as an acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from an individual’s usual seizure pattern in adult and pediatric patients 2 years of age and older. VALTOCO is a proprietary formulation of diazepam incorporating the science of INTRAVAIL®, a transmucosal absorption enhancement technology that enables the noninvasive delivery of a broad range of protein, peptide, and small-molecule drugs. For more information on VALTOCO, please visit www.valtoco.com. For the latest scientific information on VALTOCO, please visit http://www.neurelismedicalaffairs.com/. Neurelis is also developing NRL-1004, an investigational, Phase 1 stage intranasal olanzapine for treatment of acute agitation episodes associated with schizophrenia and bipolar disorder. In addition, Neurelis is also developing NRL-1049 (previously known as BA-1049), an investigational, Phase 1 new chemical entity Rho kinase (ROCK) inhibitor, for the treatment of cerebral cavernous malformations (CCMS), a rare disorder of the central nervous system (CNS). For more information on Neurelis, please visit www.neurelis.com.
Important Safety Information about VALTOCO:
Indication
VALTOCO® (diazepam nasal spray) is indicated for the acute treatment of intermittent, stereotypic episodes of frequent seizure activity (i.e., seizure clusters, acute repetitive seizures) that are distinct from a patient’s usual seizure pattern in patients with epilepsy 2 years of age and older.
WARNING: RISKS FROM CONCOMITANT USE WITH OPIOIDS; ABUSE, MISUSE, AND ADDICTION; and DEPENDENCE AND WITHDRAWAL REACTIONS
- Concomitant use of benzodiazepines and opioids may result in profound sedation, respiratory depression, coma, and death. Reserve concomitant prescribing of these drugs for patients for whom alternative treatment options are inadequate. Limit dosages and durations to the minimum required. Follow patients for signs and symptoms of respiratory depression and sedation.
- The use of benzodiazepines, including VALTOCO, exposes users to risks of abuse, misuse, and addiction, which can lead to overdose or death. Abuse and misuse of benzodiazepines commonly involve concomitant use of other medications, alcohol, and/or illicit substances, which is associated with an increased frequency of serious adverse outcomes. Before prescribing VALTOCO and throughout treatment, assess each patient’s risk for abuse, misuse, and addiction.
- The continued use of benzodiazepines may lead to clinically significant physical dependence. The risks of dependence and withdrawal increase with longer treatment duration and higher daily dose. Although VALTOCO is indicated only for intermittent use, if used more frequently than recommended, abrupt discontinuation or rapid dosage reduction of VALTOCO may precipitate acute withdrawal reactions, which can be life-threatening. For patients using VALTOCO more frequently than recommended, to reduce the risk of withdrawal reactions, use a gradual taper to discontinue VALTOCO.
Contraindications: VALTOCO is contraindicated in patients with:
- Hypersensitivity to diazepam
- Acute narrow-angle glaucoma
Central Nervous System (CNS) Depression
Benzodiazepines, including VALTOCO, may produce CNS depression. Caution patients against engaging in hazardous activities requiring mental alertness, such as operating machinery, driving a motor vehicle, or riding a bicycle, until the effects of the drug, such as drowsiness, have subsided, and as their medical condition permits.
The potential for a synergistic CNS-depressant effect when VALTOCO is used with alcohol or other CNS depressants must be considered, and appropriate recommendations made to the patient and/or care partner.
Suicidal Behavior and Ideation
Antiepileptic drugs (AEDs), including VALTOCO, increase the risk of suicidal ideation and behavior. Patients treated with any AED for any indication should be monitored for the emergence or worsening of depression, suicidal thoughts or behavior, and/or unusual changes in mood or behavior.
Glaucoma
Benzodiazepines, including VALTOCO, can increase intraocular pressure in patients with glaucoma. VALTOCO may only be used in patients with open-angle glaucoma only if they are receiving appropriate therapy. VALTOCO is contraindicated in patients with narrow-angle glaucoma.
Neonatal Sedation and Withdrawal Syndrome
Use of VALTOCO late in pregnancy can result in sedation (respiratory depression, lethargy, hypotonia) and/or withdrawal symptoms (hyperreflexia, irritability, restlessness, tremors, inconsolable crying, and feeding difficulties) in the neonate. Monitor neonates exposed to VALTOCO during pregnancy or labor for signs of sedation and monitor neonates exposed to VALTOCO during pregnancy for signs of withdrawal; manage these neonates accordingly.
Risk of Serious Adverse Reactions in Infants due to Benzyl Alcohol Preservative
VALTOCO is not approved for use in neonates or infants. Serious and fatal adverse reactions, including “gasping syndrome,” can occur in neonates and low-birth-weight infants treated with benzyl alcohol–preserved drugs, including VALTOCO. The “gasping syndrome” is characterized by central nervous system depression, metabolic acidosis, and gasping respirations. The minimum amount of benzyl alcohol at which serious adverse reactions may occur is not known.
Adverse Reactions
The most common adverse reactions (at least 4%) were somnolence, headache, and nasal discomfort.
Diazepam, the active ingredient in VALTOCO, is a Schedule IV controlled substance.
To report SUSPECTED ADVERSE REACTIONS, contact Neurelis, Inc. at 1-866-696-3873 or FDA at 1-800-FDA-1088 (www.fda.gov/medwatch).
Please read full Prescribing Information, including Boxed Warning.
Contacts:
Marie Rossi, PhD, Public and Investor Relations, media@neurelis.com, +1 858 251 2100
View original content to download multimedia:https://www.prnewswire.com/news-releases/neurelis-joins-the-epilepsy-community-at-annual-sofies-journey-epilepsy-awareness-day-and-education-expo-at-disneyland-resort-302939225.html
SOURCE Neurelis, Inc.



